The landscape of NSCLC treatment is evolving rapidly, and personalized medicine is at the forefront. Our latest blog post dives into a massive dataset of 80,000+ ALK, 35,000+ ROS1, 11,000+ EGFR, and more FISH results, shedding light on the prevalence of key mutations and the potential for more precise treatment plans. For pharmaceutical companies seeking to target clinicians and patients effectively, this data is a game-changer. Learn how these insights can revolutionize NSCLC care: https://bit.ly/3SkGEGT #NSCLC #PersonalizedMedicine #RealWorldData #PrognosHealth
Prognos Health’s Post
More Relevant Posts
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #pharma #pharmaceutical #healthcare
Google News
cgtlive.com
-
Thoughts on this? >> Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #competitivemarketing
Google News
cgtlive.com
-
Thoughts on this? >> Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech
Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma
endpts.com
-
Nuclear and breast imaging radiologist. Cancer imaging specialist and clinical researcher. Founder of The Radiology Review Podcast.
Important article for those interested in #radiopharmaceutical therapy. This is key for healthcare leaders and policymakers to get right. #theranostics #RLT https://lnkd.in/gvXbirp5
'Significant talent shortage' threatens the rise of radiopharmaceuticals
https://www.statnews.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #pharmaceutical #healthcare
Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma
endpts.com
-
Senior Director @ PSI CRO | Global Late Phase Studies Oncology, Radiopharm, Hemato-Onco, Supportive Care, IPF, Haemophilia, BD, MS, anti-infectives, anti-fungals. Long-standing PCMG Assembly Steering Committee member.
#Radiopharmaceutical clinical trials face a host of logistical challenges, often leading to delays. Learn how we leveraged proven #RLT expertise to help our sponsor meet or beat all critical milestones, securing #FDA approval in under four years. https://bit.ly/3Z4vydo #clinicaltrials #Radioligand #isotopes #clinicalresearch #psicro #radiopharmaceuticals #theranostic #diagnostic #imagingagents #oncology
Case Study: Phase 3 Radiopharmaceutical Clinical Trial in Oncology
https://psi-cro.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #biotech #pharma #healthcare
Google News
globenewswire.com
-
Clinical Trial Manager | Biomedical Scientist | Review Editor at Nature Portfolio | Avid Non-Fiction Reader | Let's Connect!
The Skyscraper-06 press release highlights concerns about combining anti-TIGIT ICIs with anti-PD-1/PD-L1 therapies, showing a cumulative negative effect (PD-L1 + Tirag + chemo, OS HR=1.33, PFS HR=1.27). Anti-TIGIT clinical trials show varied outcomes on primary endpoints. In mouse models, standalone anti-TIGIT mAbs are insufficient against subcutaneous tumors, necessitating combination therapies with PD-1 inhibitors. Regarding ICI combinations, I see two approaches: 1. The null model of drug independence suggests ICIs provide multiple opportunities for monotherapy response (not additive or synergistic), which hasn't been demonstrated effectively in anti-TIGIT studies. Combination outcomes range from mixed to cumulatively negative effects. 2. Alternatively, evaluating the Chemotherapy + anti-PD-L1 + anti-TIGIT combination in molecularly defined patient subsets remains crucial and unexplored. Most trials lean towards approach 1) for anti-TIGIT, despite the disappointing outcomes of SKYSCRAPER studies with tiragolumab. Do you think another anti-TIGIT could succeed where tiragolumab failed? Drug development is challenging. What are your thoughts on anti-TIGIT therapies? Press Release: https://lnkd.in/ggpgbRZA #Skyscraper06 #AntiTIGIT #PDL1 #ImmunoOncology
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Pointers to consider in SCLC developments >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #biotech #healthcare #pharma
Pointers to consider in SCLC developments | Biotech Strategy Blog
https://biotechstrategyblog.com
-
Thoughts on this? >> Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #competitivemarketing #healthcare
Google News
globenewswire.com
